arginyl-glycyl-aspartic acid has been researched along with nitinol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Q; Joner, M; Kessler, H; Kolodgie, FD; Laufer, B; Lopez, M; Mas-Moruno, C; Neubauer, S; Schönhofer-Merl, S; Virmani, R | 1 |
| Gries, T; Jockenhövel, S; Klee, D; Liehn, EA; Megens, RT; Möller, M; Schreiber, F; Simsekyilmaz, S; Smeets, R; Theelen, W; Weber, C; Weinandy, S; Zernecke, A | 1 |
2 other study(ies) available for arginyl-glycyl-aspartic acid and nitinol
| Article | Year |
|---|---|
Polymer-free immobilization of a cyclic RGD peptide on a nitinol stent promotes integrin-dependent endothelial coverage of strut surfaces.
Topics: Alloys; Animals; Cell Adhesion; Cells, Cultured; Coated Materials, Biocompatible; Endothelial Cells; Humans; Male; Materials Testing; Oligopeptides; Peptides, Cyclic; Rabbits; Stents; Surface Properties | 2012 |
Targeting In-Stent-Stenosis with RGD- and CXCL1-Coated Mini-Stents in Mice.
Topics: Alloys; Animals; Carotid Stenosis; Cell Adhesion; Cell Proliferation; Cells, Cultured; Chemokine CXCL1; Endothelium, Vascular; Mice; Oligopeptides; Stents | 2016 |